JP2008530090A5 - - Google Patents

Download PDF

Info

Publication number
JP2008530090A5
JP2008530090A5 JP2007555124A JP2007555124A JP2008530090A5 JP 2008530090 A5 JP2008530090 A5 JP 2008530090A5 JP 2007555124 A JP2007555124 A JP 2007555124A JP 2007555124 A JP2007555124 A JP 2007555124A JP 2008530090 A5 JP2008530090 A5 JP 2008530090A5
Authority
JP
Japan
Prior art keywords
cci
polymorph
solid
polymorph form
bme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007555124A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008530090A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/003098 external-priority patent/WO2006086172A1/en
Publication of JP2008530090A publication Critical patent/JP2008530090A/ja
Publication of JP2008530090A5 publication Critical patent/JP2008530090A5/ja
Withdrawn legal-status Critical Current

Links

JP2007555124A 2005-02-09 2006-01-25 Cci−779多形及びその使用 Withdrawn JP2008530090A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65137405P 2005-02-09 2005-02-09
PCT/US2006/003098 WO2006086172A1 (en) 2005-02-09 2006-01-25 Cci-779 polymorph and use thereof

Publications (2)

Publication Number Publication Date
JP2008530090A JP2008530090A (ja) 2008-08-07
JP2008530090A5 true JP2008530090A5 (https=) 2009-03-05

Family

ID=36570939

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007555124A Withdrawn JP2008530090A (ja) 2005-02-09 2006-01-25 Cci−779多形及びその使用

Country Status (19)

Country Link
US (1) US7442707B2 (https=)
EP (1) EP1856130A1 (https=)
JP (1) JP2008530090A (https=)
KR (1) KR20070107030A (https=)
CN (1) CN101115759A (https=)
AR (1) AR052479A1 (https=)
AU (1) AU2006213061A1 (https=)
BR (1) BRPI0607932A2 (https=)
CA (1) CA2595766A1 (https=)
CR (1) CR9257A (https=)
GT (1) GT200600044A (https=)
IL (1) IL184560A0 (https=)
MX (1) MX2007009590A (https=)
NO (1) NO20073725L (https=)
PE (1) PE20060996A1 (https=)
RU (1) RU2007129264A (https=)
TW (1) TW200638932A (https=)
WO (1) WO2006086172A1 (https=)
ZA (1) ZA200706628B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8551512B2 (en) 2004-03-22 2013-10-08 Advanced Cardiovascular Systems, Inc. Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
BRPI0619592A2 (pt) * 2005-12-07 2016-09-06 Wyeth Corp métodos para medir a qualidade da partícula de um composto de rapamicina, para determinar o tamanho de partícula médio de uma amostra e a cristalinidade de um composto de rapamicina, e para a purificação de rapamicina
AR058282A1 (es) * 2005-12-07 2008-01-30 Wyeth Corp Forma cristalina purificada de cci-779, un proceso para la preparacion del mismo, un metodo para monitorear la cristalizacion del cci-779, un kit y una composicion farmaceutica que lo comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer.
US7622578B2 (en) * 2005-12-07 2009-11-24 Wyeth Scalable process for the preparation of a rapamycin 42-ester from a rapamycin 42-ester boronate
TW200824713A (en) * 2006-10-18 2008-06-16 Wyeth Corp Processes for the synthesis of individual isomers of mono-PEG CCI-779
EP2380006A4 (en) * 2009-01-21 2012-05-16 Biocon Ltd PROCESS FOR DETERMINING THE SIROLIMUS STABILITY AND METHOD FOR PRODUCING ITS STABLE FORM
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
CN109020995A (zh) * 2017-06-12 2018-12-18 鲁南制药集团股份有限公司 一种替西罗莫司的晶型物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
TWI256395B (en) 1999-09-29 2006-06-11 Wyeth Corp Regioselective synthesis of rapamycin derivatives
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
BR0211986A (pt) * 2001-08-22 2004-09-28 Wyeth Corp 29-enóis de rapamicina
MXPA04001523A (es) 2001-08-22 2004-05-31 Wyeth Corp Dialdehidos de rapamicina.
WO2005010010A1 (en) 2003-07-16 2005-02-03 Wyeth Cci-779 isomer c
KR20060057605A (ko) 2003-08-07 2006-05-26 와이어쓰 Cci-779의 위치선택적 합성 방법
RU2345999C2 (ru) 2003-09-03 2009-02-10 Уайт Аморфный 42-эфир рапамицина и 3-гидрокси-2(гидроксиметил)-2-метилпропионовой кислоты и содержащие его фармацевтические композиции
JP4224115B2 (ja) * 2004-04-14 2009-02-12 ワイス ラパマイシン42−エステル誘導体の位置特異的合成

Similar Documents

Publication Publication Date Title
RU2007104518A (ru) Полиморф рапамицина ii и его применение
KR101454937B1 (ko) 면역조절제로서 피리딘-3-일 유도체
KR101454944B1 (ko) S1p1/edg 수용체 작동약으로서 아미노-피리딘 유도체
JP2018520178A5 (https=)
JPH0631300B2 (ja) 結晶性アジスロマイシン2水和物及びその製法
JP2008530090A5 (https=)
JP2010539237A5 (https=)
JP2007532560A5 (https=)
WO2013175506A2 (en) Process for sorafenib tosylate polymorph iii
WO2023134677A1 (zh) 制备吡咯化合物的方法及其中间体
RU2007129264A (ru) Полиморф cci-779 и его применение
EP2537832B1 (en) Method for preparing (e)-methyl 2-[2-(6-chloropyrimidin-4-yloxy)phenyl]-3-methoxyacrylate
CN107698574B (zh) 一种高纯度阿瑞匹坦的精制制备工艺
JP2022060192A5 (https=)
CA2806820A1 (en) N-methylformamide solvate of dasatinib
JP5642766B2 (ja) アデフォビルジピボキシルの新規結晶形及びその製造方法
WO2011061611A1 (en) Process for the preparation of form b of lenalidomide
WO2011147279A1 (zh) 5-[[2(r)-[1(r)-[3,5-双(三氟甲基)苯基]乙氧基]-3(s)-4-(氟苯基)-4-吗啉基]甲基]-1,2-二氢-3h-1,2,4-三唑-3-酮的制备方法
JP2008524183A5 (https=)
TW202313599A (zh) 式i化合物的晶型及其製備和應用
CA2734896A1 (en) Therapeutic substituted pyrroles
CN106432253B (zh) 一种维帕他韦新晶型及其制备方法
EP2139899A1 (en) Crystalline forms of topotecan hydrochloride and processes for making the same
US20130231363A9 (en) Alternative forms of the phosphodiesterase-4 inhibitor n-cyclopropyl-1--4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxyamide
US20080200724A1 (en) Process and Compound